Trial reportDrug design, development and therapy2025
A Randomized Placebo-Controlled Dose-Response Trial of Muvz
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The current study aimed to investigate the dose-response efficacy and safety of Muvz Patients and Methods: The study included 157 adults aged 40-60 having knee/low back joint discomfort. The primary outcome was an enhancement in the overall musculoskeletal health in 90 days. Secondary outcomes included assessing the joint discomfort following physical activity, range of motion, quality of life, and the consumption of rescue medication. Results: E-PR-01 notably enhanced musculoskeletal health in a dose-dependent manner compared to placebo within 30 days (p<0.0001), with effects persisting through day 90 and demonstrated clinically significant difference by 13 and 10 units in the HD and LD groups, respectively. Joint discomfort reduced significantly in both the E-PR-01 groups by day 90 (p<0.0001). Furthermore, both doses of E-PR-01 improved the range of motion of the assessed joint (p<0.05) and enriched participants' overall quality of life (p<0.05) at the end of the study. Conclusion: The study finds E-PR-01 effective for improving overall joint health, with the higher dose showing greater efficacy. These findings align with the earlier studies of E-PR-01 for knee and low back discomfort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.